An insight of development and validation of bioanalytical method in the reference of anticancer drugs by using LC-MS/MS

K. Praveen Kumar; Akash Marathakam; Santosh Patnaik; Sanjay Kumar; Alapati Sahithi; D. K. Shanthi Priya; Poonam Dogra

doi:10.53730/ijhs.v6nS3.7454

Authors

K. Praveen Kumar Assistant Professor, Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Govt of NCT Delhi, DPSRU, Mehrauli –Badarpur Road, PushpVihar, Sector 3, New Delhi India-110017
Akash Marathakam Professor & Head Department Chemistry, National College of Pharmacy, Kozhikode, Kerala -673602
Santosh Patnaik Assistant Professor, Department of Pharmaceutical Analysis & Quality Assurance, Royal College of Pharmacy and health sciences, Berhampur, Odisha -760002
Sanjay Kumar Dean cum Principal, School of pharmacy, Career point University Hamirpur HP 17604
Alapati Sahithi Assistant Professor, Department of Pharmaceutical Analysis, Nalla Narasimha Reddy Education Society’s Group of institutions, Majarguda, Hyderabad, -500088
D. K. Shanthi Priya Assistant Professor, Department of Pharmaceutical Analysis, Anurag University Venkatapur Ghatkesar Rd, Hyderabad Telangana-500088
Poonam Dogra Assistant Professor, School of pharmacy, Career point University Hamirpur HP 17604

Keywords:

anticancer drug, bioanalytical analysis, cancer, chromatography, liquid chromatography

Abstract

The bioanalytical analysis of anticancer agents established a more personalized treatment procedure. The importance of validating analytical procedures before they are put into normal usage is widely acknowledged. This novel approach has a lot of promise because it is quick, easy, and only requires a little amount of samples to get the accurate result. The goal of this mini review is to provide a comparative analysis of contemporary research on few anticancer agents and their methodology in reference to bioanalytical analysis. We provide practical approaches for determining extraction and clean up, precision and accuracy, selectivity and specificity, chromatographic analysis and its validation. We believe that the liquid chromatographic processes used in the bioanalysis of anticancer medicines, validation standards might have been applied in a variety of ways to counter the failure of an anticancer agent by increasing its therapeutic index approach.

Downloads

Download data is not yet available.

References

Heydari, P., Li, W., Schinkel, A. H., Beijnen, J. H., & Sparidans, R. W. et., al (2022). Development and validation of an LC-MS/MS assay for the quantification of cintirorgon (LYC-55716) in mouse plasma and tissue homogenates. Journal of pharmaceutical and biomedical analysis, 207, 114421.

ICMR-NCDIR National Cancer Registry Programme estimates 12% increase in cancer cases in the country by 2025 Cancers related to use of any form of tobacco were highest in the North-eastern region of the country

Haslam, A., Kim, M. S., & Prasad, V. et., al (2021). Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020. Annals of Oncology, 32(7), 926-932.

Di Luca, A., Henry, M., Meleady, P., & O’Connor, R.et., al (2015). Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment. DARU Journal of Pharmaceutical Sciences, 23(1), 1-13.

van Nuland, M., Venekamp, N., de Vries, N., de Jong, K. A., Rosing, H., & Beijnen, J. H. et., al (2019). Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology. Journal of Chromatography B, 1106, 26-34.

Ciocan-Cartita, C. A., Jurj, A., Buse, M., Gulei, D., Braicu, C., Raduly, L., ... & Berindan-Neagoe, I. et., al (2019). The relevance of mass spectrometry analysis for personalized medicine through its successful application in cancer “Omics”. International Journal of Molecular Sciences, 20(10), 2576.

Zanchetta, M., Iacuzzi, V., Posocco, B., Bortolin, G., Poetto, A. S., Orleni, M.,& Toffoli, G. et.,al (2021). A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring. PloS one, 16(10), e0259137.

Becher, F., Ciccolini, J., Imbs, D. C., Marin, C., Fournel, C., Dupuis, C., ... & Salas, S. et., al (2017). A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients. Scientific reports, 7(1), 1-11.

Gao, S., Tao, Z., Zhou, J., Wang, Z., Yun, Y., Li, M., ... & Miao, Y. et., al (2018). One-step solid extraction for simultaneous determination of eleven commonly used anticancer drugs and one active metabolite in human plasma by HPLC-MS/MS. Journal of Analytical Methods in Chemistry, 2018.

Mehanna, S., Bodman-Smith, K., Daher, C. F., & Khnayzer, R. S. et., al (2020). Rapid quantification of ruthenium (ii) polypyridyl anti-cancer drugs using a selective ligand dissociation LC-MS/MS method. Analytical Methods, 12(37), 4517-4525.

Wickremsinhe, E. R., & Lee, L. B.et., al (2021). Quantification of abemaciclib and metabolites: evolution of bioanalytical methods supporting a novel oncolytic agent. Bioanalysis, 13(9), 711-724.

Krull, I. S., Ding, X. D., Braverman, S., Selavka, C., Hochberg, F., & Sternson, L. A. et., al (1983). Trace Analysis for cis>-Platinum Anti-cancer Drugs via LCEC. Journal of Chromatographic Science, 21(4), 166-173.

Ravi, M., Kumar, M. S., Ushaiah, B., Prasad, C. K., Sudeepa, K., Anitha, N., ... & Devi, C. S. et.,al (2022). Design, Synthesis, Bioanalytical, Photophysical and Chemo-phototherapeutic Studies of Heteroleptic Cu (II) Complexes. Journal of the Taiwan Institute of Chemical Engineers, 132, 104112.

Mangla, B., Alam, O., Rub, R. A., Iqbal, M., Singh, A., Patel, K. S., & Kohli, K. et., al (2020). Development and validation of a high throughput bioanalytical UPLC-MS/MS method for simultaneous determination of tamoxifen and sulphoraphane in rat plasma: Application to an oral pharmacokinetic study. Journal of Chromatography B, 1152, 122260.

Bui, D., Yin, T., Duan, S., Wei, B., Yang, P., Wong, S. J., ... & Hu, M.et., al (2021). Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer. Journal of Natural Products, 84(9), 2486-2495.

Mc Laughlin, A. M., Schmulenson, E., Teplytska, O., Zimmermann, S., Opitz, P., Groenland, S. L., ... & Fuxius, S. (2021). Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. Cancers 2021, 13, 6281.

Nagar, S. et., al(2010). Pharmacokinetics of anti-cancer drugs used in breast cancer chemotherapy. Chemo Fog, 124-132.

Ekpenyong, O., Cooper, C., Ma, J., Guy, N. C., Payan, A. N., Ban, F., Xie, H. et., al (2020). Bioanalytical assay development and validation for the pharmacokinetic study of gmc1, a novel fkbp52 co-chaperone inhibitor for castration resistant prostate cancer. Pharmaceuticals, 13(11), 386.

van der Meulen, E., van Oort, I. M., Beumer, J. H., Somford, D. M., Schalken, J. A., Burger, D. M., & van Erp, N. P. et., al (2018). development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite n-desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients with Metastatic Castration-resistant prostate cancer. Mette Benoist, 40(2), 39.

Liu, Y., Lu, S., Zhao, L., Dong, X., Zhu, Z., Jin, Y., ... & Chai, Y. et., al (2018). Effects of glaucocalyxin A on human liver cancer cells as revealed by GC/MS-and LC/MS-based metabolic profiling. Analytical and bioanalytical chemistry, 410(14), 3325-3335.

Stariat, J., Šesták, V., Vávrová, K., Nobilis, M., Kollárová, Z., Klimeš, J., ...& Kovaříková, P. et., al (2012). LC-MS/MS identification of the principal in vitro and in vivo phase I metabolites of the novel thiosemicarbazone anti-cancer drug, Bp4eT. Analytical and bioanalytical chemistry, 403(1), 309-321.

Nováková, L., & Vlčková, H. et., al (2009). A review of current trends and advances in modern bio-analytical methods: chromatography and sample preparation. Analytica chimica acta, 656(1-2), 8-35.

Sharma, A., Thavathiru, E., Benbrook, D. M., & Woo, S. et., al (2017). Bioanalytical method development and validation of HPLCUV assay for the quantification of SHetA2 in mouse and human plasma: Application to pharmacokinetics study. Journal of pharmaceutical technology & drug research, 6.

Biswas, N. M., Shard, A., Patel, S., & Sengupta, P. et., al (2018). Drug development and bioanalytical method validation for a novel anticancer molecule, 4‐(dimethylamino)‐2‐(p‐tolylamino) thiazole‐5‐carbonitrile. Drug development research, 79(8), 391-399.

Cummings, J., Ward, T. H., Greystoke, A., Ranson, M., & Dive, C. et., al (2008). Biomarker method validation in anticancer drug development. British journal of pharmacology, 153(4), 646-656.

Reddy, P. A., Sahu, A. K., Sharma, M. K., & Sengupta, P. Development and Validation of a Simultaneous Bioanalytical Method for Methotrexate, Sulfasalazine and Hydroxychloroquine in Rat Plasma following Single Step Protein Precipitation Technique.

Lin, Y. T., Médioni, J., Amouyal, G., Déan, C., Sapoval, M., & Pellerin, O. et., al (2017). Doxorubicin-loaded 70–150 μm microspheres for liver-dominant metastatic breast cancer: results and outcomes of a pilot study. Cardiovascular and interventional radiology, 40(1), 81-89.

Dubbelboer, I. R., Pavlovic, N., Heindryckx, F., Sjögren, E., & Lennernäs, H. et., al (2019). Liver cancer cell lines treated with doxorubicin under normoxia and hypoxia: Cell viability and oncologic protein profile. Cancers, 11(7), 1024.

Harahap, Y., Suryadi, H., & Winarti, A. C. et., al (2020). Development and Validation of Doxorubicin Hydrochloride and Doxorubicinol in Plasma Using Liquid Chromatography-Tandem Mass Spectrometry. Systematic Reviews in Pharmacy, 11(7), 299-303.

Han, J., Zhang, J., Zhao, H., Li, Y., & Chen, Z. et., al (2016). Simultaneous determination of doxorubicin and its dipeptide prodrug in mice plasma by HPLC with fluorescence detection. Journal of Pharmaceutical Analysis, 6(3), 199-202.

Dasari, S., & Tchounwou, P. B. et., al (2014). Cisplatin in cancer therapy: molecular mechanisms of action. European journal of pharmacology, 740, 364-378.

Posocco, B., Buzzo, M., Follegot, A., Giodini, L., Sorio, R., Marangon, E., & Toffoli, G. et., al (2018). A new high-performance liquid chromatography-tandem mass spectrometry method for the determination of paclitaxel and 6α-hydroxy-paclitaxel in human plasma: Development, validation and application in a clinical pharmacokinetic study. PloS one, 13(2), e0193500.

Millet, A., Khoudour, N., Guitton, J., Lebert, D., Goldwasser, F., Blanchet, B., & Machon, C. et., al (2021). Analysis of pembrolizumab in human plasma by LC-MS/HRMS. Method validation and comparison with ELISA. Biomedicines, 9(6), 621.